Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

IMITREX

SUMATRIPTAN SUCCINATE

Standard Dose
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview IMITREX is listed in Drugs@FDA under application 020080 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SUMATRIPTAN SUCCINATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2025-12-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMITREX is listed in Drugs@FDA under application 020080 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SUMATRIPTAN SUCCINATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2025-12-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.